aluates Reports

$ 0.0

Automative

Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Research Report 2024

Published Date: June 2024

Report Code: QYRE-Auto-7E5397

Global Granulocyte Colony Stimulating Factor G CSF Drugs Market Size Status and Forecast 2021 2027

BUY CHAPTERS

Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Research Report 2024

Code: QYRE-Auto-7E5397

Report

June 2024

Pages:91

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Amgen Inc

Kyowa Kirin

Chugai Pharmaceutical

Novartis

TEVA

Pfizer Inc

Merck

Dong-A Socio

Intas

GenSci

Dr. Reddy

Amoytop

North China Pharmaceutical

SL PHARM

Hayao Group

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market

Granulocyte colony-stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.

The global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Granulocyte-Colony Stimulating Factor (G-CSF) Drugs.

Report Scope

The Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Report

Report Metric	Details
Report Name	Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market
CAGR	5%
Segment by Type	Filgrastim Pefigrastim Lipefigrastim
Segment by Application	Oncology Blood Disease Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Amgen, Kyowa Kirin, Chugai Pharmaceutical, Novartis, Teva, Pfizer, Merck, Dong-A Socio, Intas, GenSci, Dr. Reddy, Amoytop, North China Pharmaceutical, SL Pharm, Hayao Group
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market report?

Ans: The main players in the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market are Amgen, Kyowa Kirin, Chugai Pharmaceutical, Novartis, Teva, Pfizer, Merck, Dong-A Socio, Intas, GenSci, Dr. Reddy, Amoytop, North China Pharmaceutical, SL Pharm, Hayao Group

What are the Application segmentation covered in the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market report?

Ans: The Applications covered in the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market report are Oncology, Blood Disease, Other

What are the Type segmentation covered in the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market report?

Ans: The Types covered in the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market report are Filgrastim, Pefigrastim, Lipefigrastim

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Filgrastim

1.2.3 Pefigrastim

1.2.4 Lipefigrastim

1.3 Market by Application

1.3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Oncology

1.3.3 Blood Disease

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Perspective (2019-2030)

2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Growth Trends by Region

2.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Historic Market Size by Region (2019-2024)

2.2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Region (2025-2030)

2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Dynamics

2.3.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Trends

2.3.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Drivers

2.3.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Challenges

2.3.4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players by Revenue

3.1.1 Global Top Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players by Revenue (2019-2024)

3.1.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue

3.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Concentration Ratio

3.4.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue in 2023

3.5 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Key Players Head office and Area Served

3.6 Key Players Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Solution and Service

3.7 Date of Enter into Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Breakdown Data by Type

4.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Historic Market Size by Type (2019-2024)

4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Type (2025-2030)

5 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Breakdown Data by Application

5.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Historic Market Size by Application (2019-2024)

5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2019-2030)

6.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2019-2024)

6.4 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2019-2030)

7.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2019-2024)

7.4 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2019-2030)

8.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2019-2030)

9.2 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2019-2024)

9.4 Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2019-2030)

10.2 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Amgen

11.1.1 Amgen Company Detail

11.1.2 Amgen Business Overview

11.1.3 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.1.4 Amgen Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.1.5 Amgen Recent Development

11.2 Kyowa Kirin

11.2.1 Kyowa Kirin Company Detail

11.2.2 Kyowa Kirin Business Overview

11.2.3 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.2.4 Kyowa Kirin Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.2.5 Kyowa Kirin Recent Development

11.3 Chugai Pharmaceutical

11.3.1 Chugai Pharmaceutical Company Detail

11.3.2 Chugai Pharmaceutical Business Overview

11.3.3 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.3.4 Chugai Pharmaceutical Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.3.5 Chugai Pharmaceutical Recent Development

11.4 Novartis

11.4.1 Novartis Company Detail

11.4.2 Novartis Business Overview

11.4.3 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.4.4 Novartis Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.4.5 Novartis Recent Development

11.5 Teva

11.5.1 Teva Company Detail

11.5.2 Teva Business Overview

11.5.3 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.5.4 Teva Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.5.5 Teva Recent Development

11.6 Pfizer

11.6.1 Pfizer Company Detail

11.6.2 Pfizer Business Overview

11.6.3 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.6.4 Pfizer Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.6.5 Pfizer Recent Development

11.7 Merck

11.7.1 Merck Company Detail

11.7.2 Merck Business Overview

11.7.3 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.7.4 Merck Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.7.5 Merck Recent Development

11.8 Dong-A Socio

11.8.1 Dong-A Socio Company Detail

11.8.2 Dong-A Socio Business Overview

11.8.3 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.8.4 Dong-A Socio Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.8.5 Dong-A Socio Recent Development

11.9 Intas

11.9.1 Intas Company Detail

11.9.2 Intas Business Overview

11.9.3 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.9.4 Intas Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.9.5 Intas Recent Development

11.10 GenSci

11.10.1 GenSci Company Detail

11.10.2 GenSci Business Overview

11.10.3 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.10.4 GenSci Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.10.5 GenSci Recent Development

11.11 Dr. Reddy

11.11.1 Dr. Reddy Company Detail

11.11.2 Dr. Reddy Business Overview

11.11.3 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.11.4 Dr. Reddy Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.11.5 Dr. Reddy Recent Development

11.12 Amoytop

11.12.1 Amoytop Company Detail

11.12.2 Amoytop Business Overview

11.12.3 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.12.4 Amoytop Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.12.5 Amoytop Recent Development

11.13 North China Pharmaceutical

11.13.1 North China Pharmaceutical Company Detail

11.13.2 North China Pharmaceutical Business Overview

11.13.3 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.13.4 North China Pharmaceutical Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.13.5 North China Pharmaceutical Recent Development

11.14 SL Pharm

11.14.1 SL Pharm Company Detail

11.14.2 SL Pharm Business Overview

11.14.3 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.14.4 SL Pharm Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.14.5 SL Pharm Recent Development

11.15 Hayao Group

11.15.1 Hayao Group Company Detail

11.15.2 Hayao Group Business Overview

11.15.3 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Introduction

11.15.4 Hayao Group Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

11.15.5 Hayao Group Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Amgen Inc

Kyowa Kirin

Chugai Pharmaceutical

Novartis

TEVA

Pfizer Inc

Merck

Dong-A Socio

Intas

GenSci

Dr. Reddy

Amoytop

North China Pharmaceutical

SL PHARM

Hayao Group

List of Tables

Table 1. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Filgrastim

Table 3. Key Players of Pefigrastim

Table 4. Key Players of Lipefigrastim

Table 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region (2019-2024)

Table 9. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region (2025-2030)

Table 11. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Trends

Table 12. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Drivers

Table 13. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Challenges

Table 14. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Restraints

Table 15. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Players (2019-2024)

Table 17. Global Top Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs as of 2023)

Table 18. Ranking of Global Top Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Solution and Service

Table 22. Date of Enter into Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Type (2019-2024)

Table 26. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Type (2025-2030)

Table 28. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application (2019-2024)

Table 30. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Market Share by Application (2025-2030)

Table 32. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 47. Amgen Company Detail

Table 48. Amgen Business Overview

Table 49. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 50. Amgen Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 51. Amgen Recent Development

Table 52. Kyowa Kirin Company Detail

Table 53. Kyowa Kirin Business Overview

Table 54. Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 55. Kyowa Kirin Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 56. Kyowa Kirin Recent Development

Table 57. Chugai Pharmaceutical Company Detail

Table 58. Chugai Pharmaceutical Business Overview

Table 59. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 60. Chugai Pharmaceutical Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 61. Chugai Pharmaceutical Recent Development

Table 62. Novartis Company Detail

Table 63. Novartis Business Overview

Table 64. Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 65. Novartis Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 66. Novartis Recent Development

Table 67. Teva Company Detail

Table 68. Teva Business Overview

Table 69. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 70. Teva Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 71. Teva Recent Development

Table 72. Pfizer Company Detail

Table 73. Pfizer Business Overview

Table 74. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 75. Pfizer Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 76. Pfizer Recent Development

Table 77. Merck Company Detail

Table 78. Merck Business Overview

Table 79. Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 80. Merck Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 81. Merck Recent Development

Table 82. Dong-A Socio Company Detail

Table 83. Dong-A Socio Business Overview

Table 84. Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 85. Dong-A Socio Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 86. Dong-A Socio Recent Development

Table 87. Intas Company Detail

Table 88. Intas Business Overview

Table 89. Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 90. Intas Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 91. Intas Recent Development

Table 92. GenSci Company Detail

Table 93. GenSci Business Overview

Table 94. GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 95. GenSci Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 96. GenSci Recent Development

Table 97. Dr. Reddy Company Detail

Table 98. Dr. Reddy Business Overview

Table 99. Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 100. Dr. Reddy Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 101. Dr. Reddy Recent Development

Table 102. Amoytop Company Detail

Table 103. Amoytop Business Overview

Table 104. Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 105. Amoytop Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 106. Amoytop Recent Development

Table 107. North China Pharmaceutical Company Detail

Table 108. North China Pharmaceutical Business Overview

Table 109. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 110. North China Pharmaceutical Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 111. North China Pharmaceutical Recent Development

Table 112. SL Pharm Company Detail

Table 113. SL Pharm Business Overview

Table 114. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 115. SL Pharm Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 116. SL Pharm Recent Development

Table 117. Hayao Group Company Detail

Table 118. Hayao Group Business Overview

Table 119. Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product

Table 120. Hayao Group Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024) & (US$ Million)

Table 121. Hayao Group Recent Development

Table 122. Research Programs/Design for This Report

Table 123. Key Data Information from Secondary Sources

Table 124. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Type: 2023 VS 2030

Figure 3. Filgrastim Features

Figure 4. Pefigrastim Features

Figure 5. Lipefigrastim Features

Figure 6. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Application: 2023 VS 2030

Figure 8. Oncology Case Studies

Figure 9. Blood Disease Case Studies

Figure 10. Other Case Studies

Figure 11. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Report Years Considered

Figure 12. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region: 2023 VS 2030

Figure 15. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Players in 2023

Figure 16. Global Top Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue in 2023

Figure 18. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2019-2030)

Figure 20. United States Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2019-2030)

Figure 24. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Region (2019-2030)

Figure 32. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2019-2030)

Figure 40. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Share by Country (2019-2030)

Figure 44. Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Amgen Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 47. Kyowa Kirin Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 48. Chugai Pharmaceutical Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 49. Novartis Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 50. Teva Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 51. Pfizer Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 52. Merck Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 53. Dong-A Socio Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 54. Intas Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 55. GenSci Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 56. Dr. Reddy Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 57. Amoytop Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 58. North China Pharmaceutical Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 59. SL Pharm Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 60. Hayao Group Revenue Growth Rate in Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Business (2019-2024)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions